Repligen Starts RG1068 Drug Study

Repligen announces initiation of RG1068 pilot study to improve detection and characterisation of pancreatic cancer.

Biopharmaceutical company Repligen has recruited the first patient in a pilot study to evaluate the ability of RG1068, a synthetic version of the hormone secretin, to improve detection and characterisation of pancreatic cancer.

RG1068 is known to stimulate the secretion of pancreatic fluid into the pancreatic ducts and to increase blood flow to the tissues of the pancreas. In previous Phase III studies, RG1068 has shown improvement in detection of pancreatic duct abnormalities in combination with MRI in patients with pancreatitis.

The study will enrol up to 40 patients with a known or suspected pancreatic mass and will also evaluate which imaging techniqu